Just two months ago, the Coalition extended congratulations to Beijing Zizhu Pharmaceutical Co., Ltd. when its mifepristone product was prequalified by WHO. Today, we are delighted to celebrate another victory for Zizhu, a Coalition member since 2012. Zizhu’s misoprostol 200μg product has just received WHO prequalification, making it the fourth prequalified misoprostol product. Misoprostol is a uterotonic with a varied range of uses including the prevention and treatment of postpartum hemorrhage—a chief cause of maternal deaths.